loader
Please Wait
Applying Filters...

EuroAPI Header EuroAPI Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Information, Expiry & Status of FDA Orange Book Patents covering 9186346

    Client Virtual Booth
    Menu

    Sanofi

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    PharmaCompass Sponsored Ads

    Send me more info on How To Grow My Business Digitally?

    Filters Filter
    Cross PopUp
    FILTER :

    filter

    01 SANOFI AVENTIS US (2)

    filter

    01 9186346 (2)

    filter

    01 Blank (2)

    filter

    01 Blank (2)

    filter

    01 2034-02-04 (2)

    refreshReset Filter
    refreshReset Filter
    price-trendAsk Us

    SANOFI AVENTIS US

    Contact Supplier
    • FDA
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    TERIFLUNOMIDE

    PDF Supplier PDF
    URL Supplier Web Content
    9186346
    2034-02-04
    U-1786
    202992
    TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS WHILE MANAGING THE RISK OF TERIFLUNOMIDE AND ROSUVASTATIN INTERACTION BY LIMITING THE
    1
    Sanofi Company Banner

    CPhI Worldwide, Milan

    Attending

    envelop Contact Supplier

    SANOFI AVENTIS US

    Contact Supplier
    • FDA
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    TERIFLUNOMIDE

    PDF Supplier PDF
    URL Supplier Web Content
    9186346
    2034-02-04
    U-1786
    202992
    TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS WHILE MANAGING THE RISK OF TERIFLUNOMIDE AND ROSUVASTATIN INTERACTION BY LIMITING THE
    2
    Sanofi Company Banner

    CPhI Worldwide, Milan

    Attending

    envelop Contact Supplier

    Post Enquiry
    POST ENQUIRY